CTIS2022-502691-23-00进行中(未招募)1 期
Combined treatment of intraperitoneal chemotherapy after optimal interval surgery in advanced ovarian cancer - IMIB-BICOV-2022-01
Fundacion Para La Formacion E Investigacion Sanitaria De La Region De Murcia0 个研究点目标入组 20 人开始时间: 2023年6月1日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中(未招募)
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+(—)
入选标准
- •Women between 18-70 years of age with a proven histological diagnosis of FIGO stage IIIB-C/IV epithelial ovarian cancer (high-grade serous epithelial carcinoma)., CC0 complete cytoreduction without digestive anastomosis., Patients who have signed the written informed consent (IC)., Absence of extraperitoneal disease., Adequate functional status: Karnofsky index >70 or Performance status = 2, Correct liver function, defined as bilirubin <0 1.5 times the upper limit of normal (ULN), aspartate amino transferase and alanine amino transferase = 2.5 times ULN, and alkaline phosphate = 3 times ULN, Correct renal function, defined as serum creatinine = 1.5 times ULN, Acceptable bone marrow function defined as neutrophils >1.5 x 106 l-1, hemoglobin > 10 g/dl-1 and platelets >100.0 x 109 l-1, Absence of cardiac, pulmonary, hepatic, renal, or neurological disease that contraindicates major surgery., Negative result in serum and urine pregnancy test for women of childbearing age at screening visit., Administration of neoadjuvant chemotherapy with a total of 3 systemic cycles.
排除标准
- •Disease progression after initiation of systemic neoadjuvant chemotherapy., Extraperitoneal disease (including retroperitoneal nodal metastases) at reassessment after systemic neoadjuvant therapy., Impossibility of achieving complete cytoreduction (CC-0)., Active infection of any origin., Allogeneic transplant, or prior bone marrow transplant, or high-dose chemotherapy with bone marrow or stem cell rescue., Participation in a clinical trial with an investigational drug in the last 30 days., Pregnant or lactating women, where pregnancy is defined as the state of a woman after conception and until the end of gestation, confirmed by a positive human chorionic gonadotropin (hCG) test result, or who plans to become pregnant o plan to breast-feed during study treatment or within 30 days of cessation of study drug treatment., Patients with a history of allergic reactions or hypersensitivity to drugs chemically related to cisplatin and paclitaxel., Failure to sign the written informed consent.
研究者
相似试验
进行中(未招募)
1 期
Combined treatment of intraperitoneal chemotherapy after optimal interval surgery in advanced ovarian cancerOvarian cancer (OV-1)MedDRA version: 21.1Level: PTClassification code 10070907Term: Ovarian cancer stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10070908Term: Ovarian cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2022-001107-41-ESFundación para la Formación e Investigación Sanitarias de la Región de Murcia (FFIS)20
尚未招募
2 期
Determining the efficacy and safety of neoadjuvant IP chemotherapy in rectal cancer patients with the spread of disease in peritoneumCTRI/2023/11/059575Tata Memorial Hospital
招募中
不适用
Concomitant intraperitoneal and systemic chemotherapy in patients with extensive peritoneal carcinomatosis of gastric origiNL-OMON51789Erasmus MC, Universitair Medisch Centrum Rotterdam54
已完成
不适用
Concomitant intraperitoneal and systemic chemotherapy in patients with extensive peritoneal carcinomatosis of colorectal origiNL-OMON50387Erasmus MC, Universitair Medisch Centrum Rotterdam33
进行中(未招募)
不适用
Combined systemic an intrathecal chemotherapy with succeeding high dosis chemotherapy and autologous stem cell transplantation of patients with CNS relapses of agressive lymphomas. - NHL-ZNS-RezidivThe aim of the study is the prospective verification of effectiveness and compatibility of a systemic therapy with CNS passable cytostatics (high-dose Methotrexat and Ifosfamide, and high-dose Cytarabine and Thiothepa) combined with an intrathecal Depocyte therapy, followed by a High-dose dose chemotherapy with Carmustine, Thiothepa and Etoposid and an autologous stem cell transplantation.EUCTR2006-006516-30-DECharité-Universitätsmedizin Berlin
